BBIO vs. BPMC, RETA, TPTX, PRGO, BHVN, ALNY, TEVA, GMAB, RPRX, and BGNE
Should you be buying BridgeBio Pharma stock or one of its competitors? The main competitors of BridgeBio Pharma include Blueprint Medicines (BPMC), Reata Pharmaceuticals (RETA), Turning Point Therapeutics (TPTX), Perrigo (PRGO), Biohaven (BHVN), Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Royalty Pharma (RPRX), and BeiGene (BGNE).
Blueprint Medicines (NASDAQ:BPMC) and BridgeBio Pharma (NASDAQ:BBIO) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, community ranking, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.
Blueprint Medicines has higher revenue and earnings than BridgeBio Pharma. Blueprint Medicines is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.
99.9% of BridgeBio Pharma shares are held by institutional investors. 4.2% of Blueprint Medicines shares are held by company insiders. Comparatively, 24.7% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Blueprint Medicines has a net margin of -102.15% compared to Blueprint Medicines' net margin of -246.24%. Blueprint Medicines' return on equity of 0.00% beat BridgeBio Pharma's return on equity.
Blueprint Medicines currently has a consensus price target of $103.94, indicating a potential downside of 1.54%. BridgeBio Pharma has a consensus price target of $47.62, indicating a potential upside of 69.99%. Given Blueprint Medicines' stronger consensus rating and higher probable upside, analysts clearly believe BridgeBio Pharma is more favorable than Blueprint Medicines.
Blueprint Medicines received 375 more outperform votes than BridgeBio Pharma when rated by MarketBeat users. However, 68.25% of users gave BridgeBio Pharma an outperform vote while only 67.84% of users gave Blueprint Medicines an outperform vote.
Blueprint Medicines has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500.
In the previous week, BridgeBio Pharma had 13 more articles in the media than Blueprint Medicines. MarketBeat recorded 18 mentions for BridgeBio Pharma and 5 mentions for Blueprint Medicines. BridgeBio Pharma's average media sentiment score of 0.60 beat Blueprint Medicines' score of 0.47 indicating that Blueprint Medicines is being referred to more favorably in the media.
Summary
BridgeBio Pharma beats Blueprint Medicines on 11 of the 17 factors compared between the two stocks.
Get BridgeBio Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BridgeBio Pharma Competitors List
Related Companies and Tools
